Literature DB >> 12037145

G protein-coupled receptor allosterism and complexing.

Arthur Christopoulos1, Terry Kenakin.   

Abstract

G protein-coupled receptors (GPCRs) represent the largest family of cell-surface receptors. These receptors are natural allosteric proteins because agonist-mediated signaling by GPCRs requires a conformational change in the receptor protein transmitted between two topographically distinct binding sites, one for the agonist and another for the G protein. It is now becoming increasingly recognized, however, that the agonist-bound GPCR can also form ternary complexes with other ligands or "accessory" proteins and display altered binding and/or signaling properties in relation to the binary agonist-receptor complex. Allosteric sites on GPCRs represent novel drug targets because allosteric modulators possess a number of theoretical advantages over classic orthosteric ligands, such as a ceiling level to the allosteric effect and a potential for greater GPCR subtype-selectivity. Because of the noncompetitive nature of allosteric phenomena, the detection and quantification of such effects often relies on a combination of equilibrium binding, nonequilibrium kinetic, and functional signaling assays. This review discusses the development and properties of allosteric receptor models for GPCRs and the detection and quantification of allosteric effects. Moreover, we provide an overview of the current knowledge regarding the location of possible allosteric sites on GPCRs and candidate endogenous allosteric modulators. Finally, we discuss the potential for allosteric effects arising from the formation of GPCR oligomers or GPCRs complexed with accessory cellular proteins. It is proposed that the study of allosteric phenomena will become of progressively greater import to the drug discovery process due to the advent of newer and more sensitive GPCR screening technologies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037145     DOI: 10.1124/pr.54.2.323

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  289 in total

1.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 3.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators.

Authors:  Karen A Selz; Arnold J Mandell; Michael F Shlesinger; Vani Arcuragi; Michael J Owens
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 5.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 7.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 8.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

9.  [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Authors:  Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-27       Impact factor: 3.000

10.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.